Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy

Urology

Volumn 54, Issue 2, 1999, Pages 329-334

  Ahlgren, G ^a,b   Pedersen, K ^e   Lundberg, S ^d   Aus, G ^c   Hugosson, J ^c   Abrahamsson, P A ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d Jonkoping County Hospital   (Sweden)

^e RYHOV COUNTY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TUMOR BIOPSY;

CELL DIVISION; CHEMOTHERAPY, ADJUVANT; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT FAILURE;

EID: 0032770549     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00107-7     Document Type: Article

References (19)

1. Huggin C., Hodges C.V. Studies of prostatic cancer the effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate . Cancer Res. 1:1941;293-297.
2. Lepor H., Ross A., Walsh P.C. The influence of hormonal therapy on survival of men with advanced prostate cancer. J Urol. 128:1982;335-340.
3. Pound C.R., Partin A.W., Epstein J.I., et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy patterns of recurrence and cancer control . Urol Clin North Am. 24:1997;395-406.
4. van den Ouden D., Bentvelsen F.M., Boevé E.R., et al. Positive margins after radical prostatectomy correlation with local recurrence and distant progression . Br J Urol. 72:1992;489-494.
5. Ohori M., Wheeler T., Kattan M.W., et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 154:1995;1818-1824.
6. Soloway M., Sharif R., Wajsman Z., et al. Randomized prospective study comparing radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2b) prostate cancer. J Urol. 154:1995;424-428.
7. Hugosson J., Abrahamsson P.-A., Ahlgren G., et al. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neoadjuvant hormone treatment. Eur Urol. 29:1996;413-419.
8. Aus G., Hugosson J., Abrahamsson P.-A., et al. Pretreatment with Triptorelin before radical prostatectomy - a 3 year follow-up. J Urol. 159:1998;2013-2017.
9. Soloway M., Sharif R., Wajsman Z., et al. Randomized prospective study comparing radical prostatectomy preceded by androgen blockade in clinical stage cT2b prostate cancer - 24 months results. J Urol. 157:1997;160.
10. Epstein J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 71:1993;3582-3593.
11. Civantos F., Marcial M.A., Banks E.R., et al. Pathology of androgen deprivation therapy in prostate carcinoma. Cancer. 75:1995;1634-1641.
12. Bazinet M., Zheng W., Begin L.R., et al. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology. 49:1997;721-725.
13. McLeod D.G., Johnson C.F., Klein E., et al. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxM0) prostate cancer. Urology. 49:(suppl 3A):1997;70-73.
14. Cattoretti G., Becker M.H.G., Key G., et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (Mib 1 and Mib 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 168:1992;357-363.
15. McCormick D., Yu C., Hobbs C., et al. The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens. Histopathology. 22:1993;543-547.
16. Noordzij M.A., van der Kvast T.H., Steenbrugge G.J., et al. Determination of Ki-67 defined growth fraction by monoclonal antibody MIB-1 in formalin-fixed, paraffin-embedded prostatic cancer tissues. Prostate. 27:1995;154-159.
17. Parrado C., Falkmer U.G., Höög A., et al. A technique for automatic/interactive assessment of the proliferating fraction of neoplastic cells in solid tumors. Gen Diagn Pathol. 141:1995;215-227.
18. Bettencourt M.-C., Bauer J.J., Sesterhenn I.A., et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 156:1996;1064-1068.
19. Stattin P., Damber J.-E., Karlberg L., et al. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol. 157:1997;219-222.